secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001628280-24-046827
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharma receives FDA Orphan Drug and Rare Pediatric Disease designations for Ifetroban in DMD
--------------------------------------------------------------------------------

- FDA granted Orphan Drug and Rare Pediatric Disease Designations to Ifetroban for cardiomyopathy associated with Duchenne muscular dystrophy.
- Cumberland is completing the FIGHT DMD Phase II trial; results expected later in 2024.
- Rare Pediatric Disease Designation may qualify company for a priority review voucher upon approval.
- Orphan Drug Designation provides seven-year market exclusivity, tax credits, and fee waivers if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828024046827/0001628280-24-046827-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828024046827/cpix-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-046827

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer